TK-112690

• Description :

  TK-112690 is a UPP1 inhibitor. TK-112690 inhibits murine small intestinal uridine phosphorylase (UPase) with an IC50 of 12.5 μM and human small intestinal UPase with an IC50 of 20.0 μM in vitro. TK-112690 increases plasma uridine concentration in mice. TK-112690 can be used for the study of cancer and pulmonary fibrosis[1][2][3].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Others

• Related Pathways :

  Others

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Concentration :

  10mM

• Purity :

  99.91

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  CC(C1=O)=CN(C2=N1)[C@@]3([H])[C@](O2)([H])[C@@](O)([H])[C@@](O3)([H])CO

• Molecular Formula :

  C10H12N2O5

• Molecular Weight :

  240.21

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Strefeler A, et al. Nucleosides are overlooked fuels in central carbon metabolism. Trends Endocrinol Metab. 2024 Apr;35 (4) :290-299. |[2]William A. Garland, et al. Methotrexate Adjuvants to Reduce Toxicity and Methods for Using the Same. US 9,382,287 B2. United States Patent and Trademark Office (USPTO) . Jul. 5, 2016. |[3]William A. Garland, et al. Uridine Phosphorylase Inhibitors to Treat or Prevent Pulmonary Disease. US 2025/0222000 A1. United States Patent and Trademark Office (USPTO) . Jul. 10, 2025.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound2

• Clinical Information :

  No Development Reported

• CAS Number :

  [22423-26-3]